Torys LLP acted as counsel to Triumvira Immunologics on the collaboration with Merck. On January 5, 2023, Triumvira Immunologics, Inc. (“Triumvira”) announced a clinical trial collaboration...
You must be a Standard 1 Year member to access this content.
Torys LLP acted as counsel to QV Global Health Sciences Fund. Alpha-9 Theranostics Inc. announced an oversubscribed US$75 million Series B financing to advance its portfolio of...
You must be a Standard 1 Year member to access this content.
Torys LLP acted for Boondoc Technologies Incorporated on the round. Boondoc Technologies Incorporated, doing business as The Rounds, closed a Series A preferred share investment of up to...
You must be a Standard 1 Year member to access this content.
Torys LLP acted as counsel to Evotec. On May 17, 2022, Evotec SE and Sernova Corp. announced a partnership in the field of diabetes. Both Companies will leverage...
You must be a Standard 1 Year member to access this content.
Torys LLP acted as strategic advisor to the Government of Canada on the agreement. On April 29, 2022, The Canadian Prime Minister, Justin Trudeau, announced that...
You must be a Standard 1 Year member to access this content.
Latham & Watkins, Torys LLP and Goodwin represented Triumvira Immunologics in the transaction. Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell...
You must be a Standard 1 Year member to access this content.
Torys LLP acted for Entos Pharmaceuticals. On January 6, 2022, Eli Lilly and Company (NYSE:LLY) acquired exclusive rights to Entos’ Fusogenix nucleic acid delivery technology to research,...
You must be a Standard 1 Year member to access this content.
Torys LLP acted as counsel to Conavi Medical in connection with the financing. On December 15, 2021, Conavi Medical Inc. entered into agreements for over US$20...
You must be a Standard 1 Year member to access this content.
Torys LLP acted for Entos Pharmaceuticals on the deal. Entos Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc. entered into an agreement that will see Entos apply its Fusogenix nucleic...
You must be a Standard 1 Year member to access this content.
Fenwick & West LLP advised Fidelity on the deal. Torys LLP acted as counsel to Sixty Degree Capital. Fidelity Management & Research Company, the investment advisor...
You must be a Standard 1 Year member to access this content.
Fenwick & West advised T-knife Therapeutics on the deal. Torys LLP acted as counsel to Sixty Degree Capital. T-knife Therapeutics, Inc., a next-generation T-cell receptor company...
You must be a Standard 1 Year member to access this content.
Torys LLP represented Amplitude Ventures in the financing. On August 10, 2021, LQT Therapeutics, Inc. completed a US$19 million Series A financing. The financing was led by...
You must be a Standard 1 Year member to access this content.
